Navigation Links
CryoLife 2013 First Quarter Revenues Grew 10 Percent to a Record $35.5 Million
Date:4/30/2013

which we cannot market BioGlue, our products and tissues are subject to many significant risks, and we have received a warning letter from the FDA relating to our processing, preservation, and distribution of human tissue and the manufacture of medical devices and our failure to adequately address the concerns raised by the FDA in the warning letter could result in additional action being taken by the FDA, including without limitation, a recall, injunction, or legal action, which could adversely impact our revenues, profits, and liquidity, we have also received a letter from the Human Tissue Authority in London, UK, whereby it has suspended Europa's license to import human tissue, due to concerns related to the FDA warning letter, and directed Europa to issue a recall for tissues previously distributed which have not been implanted, and if we are unable to address the concerns raised by the HTA and the suspension of the import license granted by the HTA is not lifted our tissue preservation service revenues could be adversely impacted for the rest of 2013 or longer, our investment in our distribution and license and manufacturing agreements with Starch Medical, Inc. is subject to significant risks, and our ability to fully realize our investment is dependent on our ability to sell PerClot in the U.S., if we sell PerClot in the U.S., we will likely be sued for patent infringement, which will be expensive, and if we lose, we may be prohibited from selling PerClot or may have to pay substantial royalties or damages when we sell PerClot, after receiving the FDA's response to our application, we filed a revised IDE application for PerClot and we received questions from the FDA related to this filing, we are working to address the questions, but there is no guarantee that we can obtain FDA approval when anticipated, if at all, we have inherited certain risks and uncertainties related to Cardiogenesis' and Hemosphere's businesses, including that may be unable to maintain r
'/>"/>
SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results
2. CryoLife Receives FDA Clearance For Next Generation HeRO Device
3. CryoLife Expands Stock Repurchase Program
4. CryoLife 2012 Annual Revenues Grew to a Record $131.7 Million
5. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
6. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
7. CryoLife Receives Expanded Indication for BioFoam in Europe
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
10. CryoLife Announces Initiation of Quarterly Cash Dividend
11. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015  American Biosurgical, LLC ("ABI") ... cable manufacturer actively engaged in the design, development ... the world,s leading medical device companies has announced ... low volume custom medical cable manufacturer based in ... MTI brand under the name MTI Medical Cables.  ...
(Date:3/3/2015)... -- Columbia Laboratories, Inc. (Nasdaq: CBRX ) (" ... pharmaceutical company focused on pharmaceuticals for women,s health, today ... ROTH Conference, which will take place from March 8-11 ... Point, California . Management,s presentation will take place ... (12:00 p.m. Eastern Time) in the Promenade room. ...
(Date:3/3/2015)... - Sante Medical Hair Restoration is now offering the ... The ARTAS Robotic System is a state-of-the-art ... for transplantation. This latest development in minimally-invasive hair ... linear scar. "The ARTAS technology extends ... surgery." says Dr. Louis Grondin , Medical ...
Breaking Medicine Technology:American Biosurgical Acquires MTI Corporation 2No linear scar. Permanent results. 2
... Children,s Oncology Group Report Shows the Addition of ... of Death by 30% in Osteosarcoma Patients, ... IDMI ) today announced the Journal of ... 3 mifamurtide (L-MTP-PE) clinical trial,(INT-0133), entitled "Osteosarcoma: The ...
... Show Subjects Receiving,Infrequently Administered Ustekinumab Maintained Improvement from Psoriasis ... ... SAN ANTONIO, Feb. 2 One-year data from a second,double-blind, ... weeks provided sustained, clinically meaningful,improvement in the treatment of moderate ...
Cached Medicine Technology:IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 2IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 3IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 4IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 5IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 6IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 7Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 2Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 3Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 4Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 5
(Date:3/3/2015)... 03, 2015 On February 21st, the ... fabulous EcoLuxe Lounge, a day-long event that features a ... products and services. Organized by Debbie Durkin and Durkin ... placement producer, the EcoLuxe Lounge saw many notable attendees. ... on General Hospital, The Flash, Star Trek: Deep Space ...
(Date:3/3/2015)... CA (PRWEB) March 03, 2015 Findings ... , Researchers at UC Davis have developed and characterized ... cancer cells, causing them to self-destruct. This novel mechanism ... responsible for a usually fatal type of brain cancer ... cancers. , The article, to be published in ...
(Date:3/3/2015)... The Rheumatology Nurses Society (RNS) ... care and safe practice for patients with rheumatic diseases. ... biologic infusions are administered in an infusion center, provider’s ... registered nurse (RN), as defined in their State Nurse ... patients receiving these medications during a first infusion, as ...
(Date:3/3/2015)... TX (PRWEB) March 04, 2015 The ... information on the therapeutic development for Alopecia. Alopecia is ... are the two main types of alopecia. Causes for ... disorder. Symptoms of alopecia may include male pattern hair ... broken hair. Alopecia can be classified as focal or ...
(Date:3/3/2015)... March 03, 2015 Daylight Savings Time may ... Kothare, MD, has tips for parents. , Parents and their ... at 2:00 a.m. when they set their clocks forward one ... up that day -- one hour earlier -- you will ... parents should start thinking about “sleep hygiene” for their kids ...
Breaking Medicine News(10 mins):Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2
... Researchers at The Wistar Institute announce the discovery of ... with human papillomavirus (HPV). Their results, in both ... inhibitors protect a tumor-suppressing protein targeted by viral proteins, ... scientists presented their findings in the April 20 issue ...
... are testing whether different doses of an established blood pressure ... in people with mild hypertension, possibly with fewer side effects ... funded with a $1.9 million grant from the National Heart ... in the United States. The study drug, carvedilol ...
... April 26 (HealthDay News) -- The fourth National Prescription Drug ... 2 p.m., the U.S. Drug Enforcement Administration says. The ... and unused prescription drugs. At the third Take-Back Day ... tons) of unwanted or expired medications at more than 5,300 ...
... WEDNESDAY, April 25 (HealthDay News) -- Urban areas contaminated decades ... of aggravated assault, according to a new study. The ... dust emitted from older vehicles that ran on leaded gasoline, ... paint could have played a role as well. ...
... rs1051730-rs16969968 genotype and objective measures of tobacco exposure, which ... entirely, mediated by level of tobacco exposure, according to ... of the National Cancer Institute . The rs1051730-rs16969968 ... smoking, lung cancer risk, and other smoking-related outcomes. Prior ...
... are proposing a new model of care collaboration ... with various emergent cardiovascular conditions which require rapid, ... mortality, in an article published April 24 in ... ST-segment elevation myocardial infarction (STEMI), non-STEMI/unstable angina, out-of-hospital ...
Cached Medicine News:Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3Health News:URMC clinical trial tests new regimen for hypertension 2Health News:Leaded Gas Exposure Linked to Later Violence: Study 2Health News:Genetic variants, tobacco exposure and lung cancer risk 2Health News:Is it time for regional cardiovascular emergency care systems across the US? 2
... low cost, low volume alternative. Whole blood is ... separated from whole blood by centrifugation in a ... the Cebus single use cartridge. The cartridge is ... activate the concentrating process. Finally, the cartridge is ...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
... device restores lordosis and ... less reaming of the ... Danek's Tapered Laparoscopic Instruments ... and reproducibly place the ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int...
Medicine Products: